Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix (NASDAQ: NBTX) has reported its latest voting rights and share capital status as of July 31, 2025. The company disclosed a total of 48,236,671 shares outstanding, with 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, with dual listings on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

News Market Reaction – NBTX

+7.33%

2 alerts

+7.33% News Effect

+2.7% Peak Tracked

+$30M Valuation Impact

$436M Market Cap

0.2x Rel. Volume

On the day this news was published, NBTX gained 7.33%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $30M to the company's valuation, bringing the market cap to $436M at that time.

Data tracked by StockTitan Argus on the day of publication.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE) --

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
July 31, 2025	48,236,671	50,340,736	50,318,618

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

________________
¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Attachment

• 2025-08-27 -- NBTX -- Voting Rights & Shares Capital -- FINAL

FAQ

What is the current number of outstanding shares for Nanobiotix (NBTX) as of July 2025?

As of July 31, 2025, Nanobiotix has 48,236,671 shares outstanding.

How many voting rights does Nanobiotix (NBTX) have as of July 2025?

Nanobiotix has 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights as of July 31, 2025.

What are the main technology platforms of Nanobiotix (NBTX)?

Nanobiotix owns over 25 patent families across three nanotechnology platforms focused on: 1) oncology, 2) bioavailability and biodistribution, and 3) disorders of the central nervous system.

Where is Nanobiotix (NBTX) listed and headquartered?

Nanobiotix is headquartered in Paris, France and is dual-listed on Euronext Paris (since 2012) and the Nasdaq Global Select Market (since December 2020).